Janus Associated Kinase Inhibitors in Pharmacological Therapy
December 2016
Studysummary This review discusses the approved uses and adverse reactions of JAK inhibitors, noting their importance in treating various conditions but highlighting significant hematological and immunological risks. Our plain-language summary of this paper — not a Tressless recommendation.
The document reviewed studies on Janus kinase (JAK) inhibitors, highlighting their significant therapeutic effects on conditions like cancer, autoimmune diseases, and inflammatory disorders. Notably, JAK-STAT signaling inhibition was shown to promote hair growth, as demonstrated in a 2015 study by Harel et al. JAK inhibitors such as tofacitinib and ruxolitinib were effective in treating ulcerative colitis, psoriasis, and myelofibrosis, reducing inflammation, improving skin barrier function, and controlling HIV-1 viral replication. Despite their promise in various therapeutic areas, the document did not specify the number of participants in these studies.
